Kelley, Robin KateRobin KateKelleyRimassa, LorenzaLorenzaRimassaANN-LII CHENGKaseb, AhmedAhmedKasebQin, ShukuiShukuiQinZhu, Andrew XAndrew XZhuChan, Stephen LStephen LChanMelkadze, TamarTamarMelkadzeSukeepaisarnjaroen, WattanaWattanaSukeepaisarnjaroenBreder, ValeryValeryBrederVerset, GontranGontranVersetGane, EdwardEdwardGaneBorbath, IvanIvanBorbathRangel, Jose David GomezJose David GomezRangelRyoo, Baek-YeolBaek-YeolRyooMakharadze, TamtaTamtaMakharadzeMerle, PhilippePhilippeMerleBenzaghou, FawziFawziBenzaghouBanerjee, KamalikaKamalikaBanerjeeHazra, SaswatiSaswatiHazraFawcett, JonathanJonathanFawcettYau, ThomasThomasYau2023-01-122023-01-122022-081470-2045https://scholars.lib.ntu.edu.tw/handle/123456789/627206Cabozantinib has shown clinical activity in combination with checkpoint inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma.enRENAL-CELL CARCINOMA; BEVACIZUMAB; COMBINATIONCabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trialjournal article10.1016/S1470-2045(22)00326-6357980162-s2.0-85134753909WOS:000874890400020https://api.elsevier.com/content/abstract/scopus_id/85134753909